QUINAZOLINE DERIVATIVE, COMPOSITION HAVING THE DERIVATIVE, AND USE OF THE DERIVATIVE IN PREPARING MEDICAMENT
申请人:Wang Shulong
公开号:US20150080392A1
公开(公告)日:2015-03-19
A class of quinazoline derivatives or pharmaceutically acceptable salts or solvates thereof with novel structures is provided; meanwhile, a pharmaceutical composition comprising a pharmaceutically effective amount of said quinazoline derivatives or pharmaceutically acceptable salts or solvates thereof, and pharmaceutically acceptable excipients or additives is also provided. By modifying and transforming the quinazoline and screening of the transformed compounds on the activity of tyrosine kinase inhibition, most of the compounds have been found to possess inhibitory activity against one or several of EGFR, VEGFR-2, c-erbB-2, c-erbB-4, c-met, tie-2, PDGFR, c-src, lck, Zap70 and fyn kinases. The present invention has the advantages of reasonable design, broad source of and easy access to the raw materials, simple and easy operation of the preparation methods, mild reaction conditions, high yield of the products and being beneficial for industrial-scale production.
提供一类具有新颖结构的喹唑啉衍生物或其药用可接受的盐或溶剂;同时,还提供了一种包含所述喹唑啉衍生物或其药用可接受的盐或溶剂的药物组合物,以及药用可接受的赋形剂或添加剂。通过修改和转化喹唑啉,并对转化后的化合物在酪氨酸激酶抑制活性上的筛选,发现大多数化合物对EGFR、VEGFR-2、c-erbB-2、c-erbB-4、c-met、tie-2、PDGFR、c-src、lck、Zap70和fyn激酶中的一个或几个具有抑制活性。本发明具有设计合理、原料来源广泛且易获得、制备方法简单易行、反应条件温和、产品产率高且有利于工业规模生产的优点。